Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Columbia Care Reports Q2 2022 Financial Results

  • Quarterly Revenue of $123 Million, an Increase of 43% YoY
  • Gross Profit of $57 Million, an Increase of 68% YoY
  • Gross Margin of 46%, an Increase of 676bps YoY, 149bps QoQ Over Prior Adjusted Gross Margin1
  • Adjusted EBITDA of $17 Million, an Increase of 355% YoY and Adjusted EBITDA Margin1 of 14%, an increase of 930bps YoY
  • Reiterates 2022 Guidance of $625M – $675M Revenue, $120M – $135M Adjusted EBITDA

Columbia Care Inc. (OTCQX: CCHWF) today reported financial and operating results for the first quarter ended March 31, 2022. All financial information presented in this release is in U.S. GAAP, unaudited and in thousands of U.S. dollars, unless otherwise noted, and comparisons to prior quarter and prior year are made on an as-converted basis under U.S. GAAP, unless otherwise noted.

Cannabis Stock Predictor

“The results of the first quarter of 2022 demonstrate how Columbia Care overcame a number of macro-economic headwinds by exercising strong operational discipline. We materially increased our gross and EBITDA margins, as we continued leveraging the scale we have built across our strategic national platform. During the first quarter, we drove a revenue increase of 43% over the prior year, achieved nearly 700 basis points of improvement in Adjusted Gross Margin and more than 930 basis points in Adjusted EBITDA Margin. As our recent capital investments yield enhanced efficiencies throughout the value chain, this will not only allow us to capitalize on our growth opportunities throughout the country, but continue to further improve profitability,” said Nicholas Vita, CEO of Columbia Care. “As 2022 continues to unfold, our priority is on driving profitability. We expect market specific cyclicality to be surpassed by the standout growth in several key markets in our diversified portfolio. Having new, high growth markets come on line, beginning in 2Q, will provide a strong counterbalance as several maturing markets show the impact of inflationary and competitive pressures.”

Vita continued, “We are excited about recent achievements and progress thus far in 2022, including our fourth dispensary in the rapidly expanding market of Virginia, opening four retail locations and launching the leading wholesale operation in West Virginia, and the launch of adult use in New Jersey in mid-April. As we look ahead to the remainder of the year, we are leaning in to the markets that will propel growth such as New Jersey, Virginia, West Virginia, and New York, making ongoing operational improvements to drive efficiencies in new and maturing markets, and focusing on driving free cash flow to fund our growth strategy. We also remain determined to deliver the best outcome for our stakeholders as we progress towards a successful close of the transaction with Cresco Labs, with the shared vision of creating the definitive market leader in the cannabis industry.”

1 See “Non-GAAP Financial Measures” in this press release for more information regarding the Company’s use of non-GAAP financial measures.

First Quarter 2022 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items):

Q1 2022 Q4 2021 Q1 2021 % QoQ % YoY











Gross Profit











Adj. Gross Profit[1,2]











Adj. Gross Margin[1,2]







149 bps 676 bps
Adj. EBITDA[2]












Excludes $4.7 million in Q4 2021 and $0.1 million in Q1 2021 related to the mark-up of inventory acquired in acquisitions.


Non-GAAP Measure

Top 5 Markets by Revenue in Q1[3]California, Colorado, Massachusetts, Pennsylvania, Virginia

Top 5 Markets by Adjusted EBITDA in Q1[3]Colorado, Maryland, Massachusetts, Pennsylvania, Virginia


Markets are listed alphabetically

Operational Highlights for First Quarter 2021

Building scale with continued retail expansion:

  • Opened 5 additional retail locations in Q1: 4 in West Virginia and 1 in Virginia Beach, VA to bring active total to 84
  • Additional dispensaries in development include 8 in Virginia, 1 in West Virginia, and 1 in New Jersey
  • Virginia is now a Top 5 Market for both Revenue and Adjusted EBITDA with 4 active retail locations, with significant expansion of the medical program to begin July 1

Proven cultivation expertise and execution:

  • In Q1, operationalized the largest wholesale operation in West Virginia
  • Commercialized flower harvests from Riverhead, New York greenhouse for the medical market, helping to drive 1 million grams QoQ increase in finished flower grams
  • Continued to drive operational improvements and adherence to national cultivation SOPs, leading to increases in potency and yield throughout the cultivation portfolio

Sustained momentum on branding initiatives at retail and product levels:

  • In-house brands reached a record percentage of total revenue, supporting Gross Margin expansion; owned brands made up 69% of flower sales at Columbia Care locations
  • Subsequent to quarter close, launched Seed & Strain and Classix in Colorado market; Classix is now available in 13 markets and Seed & Strain is now available in 12 markets
  • Growth of in-house brands supports ability to exercise pricing discipline and Gross Margin
  • Converted Brooklyn, New York location to Cannabist retail experience; 31 Cannabist locations nationwide out of 84 active retail locations

Columbia Care Reports Q2 2022 Financial Results

Capital Markets & Liquidity Highlights

  • On February 3, 2022, Company completed a private placement of $185 million aggregate principal amount of 9.50% senior-secured first-lien notes due 2026
  • The Company exited Q1 2022 with $168.4 million in cash, up $86.2M from Q4 2021

2022 Outlook


U.S. GAAP Guidance


$625M to $675M

Adjusted EBITDA (Non-GAAP)

$120M to $135M

At this time, Columbia Care’s 2022 outlook does not include any contribution from future acquisitions, nor does it assume any additional changes in the regulatory environment in markets where Columbia Care currently operates or the anticipated impact of the pending Cresco Labs transaction. This also excludes potential future market changes where a conversion from medical only to adult use is under consideration by a governor and/or legislature. See “Caution Concerning Forward-Looking Statements” below for further discussion.

Columbia Care Reports Q2 2022 Financial Results

About Cannin: Your Cannabis Stocks Resource

78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.

Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021. 

Use Cannin as your resource for:

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.

Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +34% Gains in 2022
  • +56% Gains in 2021
  • +30% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at